In Vitro and In Vivo Characterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile

Схожие документы

• Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens
  по: Snydman, D. R., et al.
  Опубликовано: (2012)
• In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species
  по: Citron, Diane M., et al.
  Опубликовано: (2012)
• Genetically Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with Improved Properties
  по: Nguyen, Kien T., et al.
  Опубликовано: (2010)
• Daptomycin Antibiotic Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections
  по: Van Praagh, Andrew D. G., et al.
  Опубликовано: (2011)
• Surotomycin Demonstrates Low In Vitro Frequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium
  по: Mascio, Carmela T. M., et al.
  Опубликовано: (2014)